WallStreetZenWallStreetZen

NASDAQ: ORGS
Orgenesis Inc Earnings & Revenue

OverviewEarnings
DividendOwnership

ORGS past earnings growth

How has ORGS's earnings growth performed historically?
Company
223.73%
Industry
51.77%
Market
62.15%
ORGS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ORGS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
ORGS's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

ORGS past revenue growth

How has ORGS's revenue growth performed historically?
Company
-98.53%
Industry
148.64%
Market
17.33%
ORGS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ORGS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

ORGS earnings and revenue history

Current Revenue
$530.0k
Current Earnings
-$55.4M
Current Profit Margin
-10,445.5%

ORGS Return on Equity

Current Company
N/A
Current Industry
-63.5%
Current Market
188%
ORGS's Return on Equity (-514.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ORGS announces earnings.

ORGS Return on Assets

Current Company
-178.1%
Current Industry
2.9%
ORGS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ORGS Return on Capital Employed

Current Company
2,824.2%
Current Industry
19.5%
ORGS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ORGS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ORGS$530.00k-$50.83M-$55.36M-39.28%+1.92%
BNTC$61.00k-$21.44M-$21.81M+62.56%N/A
NERV$0.00-$29.97M-$30.01M-100.00%N/A
PMCB$0.00-$1.14M-$11.51MN/AN/A
VBIV$8.68M-$84.45M-$93.84M+20.94%N/A
View Top Biotech Stocks

ORGS earnings dates

Next earnings date
May 8, 2024

Orgenesis Earnings & Revenue FAQ

What were ORGS's earnings last quarter?

Orgenesis (NASDAQ: ORGS) reported Q4 2023 earnings per share (EPS) of $0.21, up 31.25% year over year. Total Orgenesis earnings for the quarter were -$6.62 million. In the same quarter last year, Orgenesis's earnings per share (EPS) was $0.16.

If you're new to stock investing, here's how to buy Orgenesis stock.

What was ORGS's earnings growth in the past year?

As of Q2 2024, Orgenesis's earnings has grown 223.73% year over year. This is 171.96 percentage points higher than the US Biotechnology industry earnings growth rate of 51.77%. Orgenesis's earnings in the past year totalled -$55.36 million.

What is ORGS's earnings date?

Orgenesis's earnings date is Invalid Date. Add ORGS to your watchlist to be reminded of ORGS's next earnings announcement.

What was ORGS's revenue last quarter?

Orgenesis (NASDAQ: ORGS) reported Q4 2023 revenue of $165.00 thousand up 98.79% year over year. In the same quarter last year, Orgenesis's revenue was $13.62 million.

What was ORGS's revenue growth in the past year?

As of Q2 2024, Orgenesis's revenue has grown -98.53% year over year. This is 247.17 percentage points lower than the US Biotechnology industry revenue growth rate of 148.64%. Orgenesis's revenue in the past year totalled $530.00 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.